Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older.
- People who have been diagnosed with skin melanoma (cutaneous melanoma) that is either at an advanced stage that cannot be surgically removed (stage III unresectable) or has spread to other parts of the body (stage IV), confirmed by tissue testing.
- People whose tumour has been tested for a protein called PD-L1, with treatment planned based on those results, as decided by their treating cancer doctor.
- People for whom a specific type of immunotherapy — Nivolumab alone, Nivolumab combined with Ipilimumab, or Nivolumab combined with Relatlimab — has been planned as standard treatment by their treating cancer doctor.
- People whose cancer can be measured using CT or MRI scans according to a standard measurement system called RECIST 1.1.
- People who are generally well enough to carry out daily activities, rated 0 or 1 on a standard medical scale called the ECOG performance scale (meaning fully active or able to do light activity).
- People whose blood test results before starting treatment meet specific levels for white blood cells, neutrophils (infection-fighting cells), platelets, haemoglobin, kidney function, and liver function (confirm with trial site for exact values).
- People who have finished palliative radiotherapy at least 2 weeks before starting the trial treatment.
- People of reproductive potential who are willing to use adequate contraception throughout the trial.
- People who are willing and able to sign a written consent form.
Who may not be able to join:
- People who currently have active cancer that has spread to the brain.
- People who have had a different cancer in the past, unless they have been in complete remission for at least 2 years before joining the trial.
- People who have previously received systemic (whole-body) anti-cancer treatment for unresectable or metastatic melanoma.
- People with a serious, uncontrolled medical condition or active infection that, in the trial doctor's opinion, could increase the risks of participation or interfere with treatment.
- People who have an active autoimmune disease (where the immune system attacks the body's own tissues).
- People who have needed to take corticosteroids (such as prednisone) or other immune-suppressing medications regularly within the 14 days before starting treatment.
- People who have taken part in another clinical drug or medical device trial within 30 days before starting this trial.
- People who have active Hepatitis B, active Hepatitis C, or active HIV infection.
- People who have had a severe allergic reaction to a type of medication called monoclonal antibodies in the past.
- People who are pregnant or breastfeeding.
- People of reproductive potential who are not willing to use effective contraception.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +39 08117775088
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
the role of immunonutrition with Oral Impact® in reducing G3 - G4 irAEs frequency and severity grade of anti-PD1 therapy (Nivolumab) or anti-PD1 based regimen in patients with inoperable locally advanced or metastatic melanoma.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.